Navigation Links
Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
Date:7/23/2013

New York, NY (PRWEB) July 23, 2013

Signal Genetics today announced that the results of a retrospective Weill Cornell validation study of BreastPRS, a novel series of prognostic and molecular profiling algorithms for breast cancer, has been published in the medical journal ‘Breast Cancer Research and Treatment’. Signal Genetics, LLC, is a privately held molecular diagnostic company based in New York, NY and Little Rock, AR.

Ryan Van Laar, Ph.D., Head of Bioinformatics & New Product Development at Signal Genetics said “We are excited about the results of this independent study, which determines that our BreastPRS test has the potential to provide physicians improved breast cancer prognostication and more critical personalized information. It is now much more than a viable alternative.”

The publication is titled “BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.”[1]. The study was performed by re-analyzing breast cancer tissue from 246 Weill Cornell patients whose tissue had previously been analyzed with Oncotype DX® by Genomic Health® (CA) . Gene expression analysis and BreastPRS calculations were performed in Signal Genetics’ CLIA-certified laboratory in Little Rock, AR.

The correlation between recurrence score and risk groups generated from the Oncotype DX and BreastPRS methods was highly statistically significant (P < 0.0001). Notably BreastPRS was found to reclassify Oncotype DX intermediate-risk patients into two groups with significant differences in recurrence free survival, potentially offering physicians an alternative method of breast cancer prognostication, which includes molecular grade and molecular subtyping algorithms to provide a comprehensive personalized analysis of each patient’s disease.

BreastPRS has also been used by researchers at the Windber Research Institute (Windber, PA) to examine the impact of recent ASCO/CAP guideline changes for determining ER status. The study was published in the Annals of Surgical Oncology (2013 Jan; 20(1): 87-93)

Signal Genetics is seeking licensing partners to further develop BreastPRS as a stand-alone prognostic test for patients with breast cancer. For more information contact Signal Genetics by emailing info(at)signalgenetics(dot)com.

[1] Timothy M. D’Alfonso, et al. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast Cancer Research and Treatment. June 2013, Volume 139, Issue 3, pp 705-715

Genomic Health and Oncotype DX are registered trademarks of Genomic Health, Inc.

Read the full story at http://www.prweb.com/releases/signalgenetics/breastprs/prweb10947060.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Needle beam could eliminate signal loss in on-chip optics
2. Physicists skirt thermal vibration, transfer optical signal via mechanical oscillator
3. Laser-like photons signal major step towards quantum Internet
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
6. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
10. Cytogenetics - Technologies, Markets and Companies
11. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):